Viewing StudyNCT05169567



Ignite Creation Date: 2024-05-06 @ 5:01 PM
Last Modification Date: 2024-10-26 @ 2:20 PM
Study NCT ID: NCT05169567
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2024-06-26
First Post: 2021-12-22

Brief Title: Abemaciclib LY2835219 Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer
Sponsor:
Organization: Eli Lilly and Company

Study Design

Study Type: INTERVENTIONAL
Expanded Access Type Individual: None
Expanded Access Type Intermediate: None
Expanded Access Type Treatment: None
Patient Registry: None
Target Duration: None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention: None
Bio Spec Description: None
Enrollment Count: 368
Enrollment Type: ACTUAL
Design Primary Purpose:
Design Masking:
Phases:
Name
PHASE3
Observational Models:
Time Perspective List:
Who Masked List: